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ABSTRACT 
Oncolytic viral (OV) therapy has been considered as a promising treatment modality for 
brain tumors. Vasculostatin, the fragment of brain-specific angiogenesis inhibitor-1, 
shows anti-angiogenic activity against malignant gliomas. Previously, a 
vasculostatin-expressing oncolytic HSV-1, Rapid Antiangiogenesis Mediated By 
Oncolytic virus (RAMBO), was reported to have a potent antitumor effect. Here, we 
investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, 
combination therapy for malignant glioma. In vitro, tube formation was significantly 
decreased in RAMBO and cilengitide combination treatment compared to RAMBO or 
cilengitide monotherapy. Moreover, combination treatment induced a synergistic 
suppressive effect on endothelial cell migration compared to the control virus. RAMBO, 
combined with cilengitide, induced synergistic cytotoxicity on glioma cells. In the 
caspase-8 and -9 assays, the relative absorption of U87ΔEGFR cell clusters treated with 
cilengitide and with RAMBO was significantly higher than of those treated with control. 
In addition, the activity of caspase 3/7 was significantly increased with combination 
therapy. In vivo, there was a significant increase in the survival of mice treated with 
combination therapy compared to RAMBO or cilengitide monotherapy. These results 
indicate that cilengitide enhanced vasculostatin-expressing OV therapy for malignant 
glioma and provide a rationale for designing future clinical trials combining these two 
agents. 
 
Introduction 
Glioblastoma multiforme (GBM) is the most frequent primary malignant brain tumor in 
adults. Pathologically, GBM is characterized by features of malignancy including 
marked neovascularity, rapid cell proliferation, infiltrative cell migration, and extensive 
necrosis. The median survival of patients remains at 14–16 months and the 5-year 
survival rate is less than 3% 1, even if the most aggressive treatment is attempted. Given 
the poor prognosis of this disease, there is a desperate need for novel methods of 
intervention including oncolytic therapy and molecular targeted therapy 2. 
Oncolytic viral (OV) therapy is an emerging biological treatment modality that 
exploits the tumor-specific properties of some viruses 3. Oncolytic herpes simplex 
viruses (HSVs) are genetically engineered to replicate selectively in and lyse tumor cells, 
but cause minimal damage to normal tissue. Vasculostatin (Vstat120) is the 
extracellular fragment of brain-specific angiogenesis inhibitor 1, and has been shown to 
be a potent antiangiogenic and antitumorigenic factor 4. We have created an armed 
oncolytic HSV-1 that expresses Vstat120 under the control of an immediate early IE4/5 
HSV promoter 5. On the basis of its potent and rapid induction of antiangiogenic 
Vstat120, we named this virus Rapid Antiangiogenesis Mediated By Oncolytic virus 
(RAMBO). Treatment of mice bearing intracranial and subcutaneous gliomas revealed a 
significant increase in the antitumor efficacy of RAMBO compared to the control virus.  
Integrins control the attachment of cells to the extracellular matrix (ECM) and 
participate in cellular defense against genotoxic assaults 6. Integrins are expressed  in 
tumor cells and tumor endothelial cells 7-9, and they play important roles in angiogenesis 
and invasion in glioma 10-12. The integrins αvβ3 and αvβ5 regulate cell adhesion 13, 14, 
and inhibitors of these integrins suppress tumor growth in certain pre-clinical models 15. 
Therefore, integrins have attracted attention as potential therapeutic targets in glioma. 
Several integrin-targeted drugs are in clinical trials as potential compounds for the 
treatment of cancer. Among them, cilengitide (EMD121974) is a novel integrin 
antagonist for the treatment of glioblastoma 16. Cilengitide is currently being assessed in 
phase III trials for glioblastoma patients and phase II trials for other types of cancers, 
with promising therapeutic outcomes reported  to date. Several preclinical studies have 
shown an enhanced antitumor effect of cilengitide when administered in combinatorial 
therapeutic regimens 17-20. 
Previously, we presented an in vivo study of OV therapy – induced changes in tumor 
blood vessels and the impact of modulating tumor vasculature on the efficacy of OV 
therapy in a rat glioma model 21. OV treatment of rat gliomas increased the permeability 
of the tumor vasculature, tumor inflammation, and leukocyte infiltration 22, 23. 
Pretreatment of gliomas with cilengitide reduced inflammation, vascular 
hyperpermeability, and leukocyte infiltration of tumor tissue following treatment with 
an oncolytic virus and enhanced the anticancer efficacy of OV treatment by increasing 
viral propagation in tumors. In this study, we demonstrate that RAMBO and cilengitide 
combination treatment of glioma. An evaluation of the cytotoxic mechanism revealed 
the increased activation of multiple caspase molecules in cells treated with cilengitide 
and RAMBO and cilengitide combined. We also demonstrate that cilengitide auguments 
the therapeutic effect of the vasculostatin-expressing oncolytic virus for malignant 
glioma by systemic injection.  
 
Materials & Methods 
Cell lines, viruses, and reagents 
U87ΔEGFR, Gli36, U251, human glioma cells, and Vero cells were prepared and 
maintained as described previously24. Glioma cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
at 37°C and 5% CO2.  
HSVQ is an HSV-1-derived recombinant oncolytic virus with a disrupted UL39 
locus and deletions in both copies of the γ34.5 gene25. The HSV-1-derived oncolytic 
virus named RAMBO was used to incorporate the cDNA encoding for human 
vasculostatin, driven by the HSV-1 IE4/5 promoter. 
Cilengitide was generously provided by Merck KgaA (Darmstadt, Germany) and the 
Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of 
Health.  
 
Immunocytological analysis 
U251, Gli36, and U87ΔEGFR glioma cells were seeded onto 4-Chamber Polystyrene 
Vessel Tissue Culture Treated Glass Slides (BD Falcon, Franklin Lakes, NJ, USA) and 
incubated overnight. For immunofluorescence, the cells were fixed in 4% 
paraformaldehyde in PBS for 15 min. After the cells were fixed, they were rinsed three 
times with PBS. Nonspecific binding was blocked by incubation in a blocking buffer 
containing 2% bovine serum albumin (BSA) in PBS for 30 min at room temperature. 
The cells were incubated overnight at 4°C with a mouse monoclonal anti-human 
integrin αvβ3 antibody (CHEMICON MAV1976) or mouse monoclonal anti-human 
integrin αvβ5 antibody (Abcam, Cambridge, MA, USA), which were diluted 1:100 and 
1:500 in blocking buffer, respectively.  
The cells were washed in blocking buffer 3 times for 5 min before incubation with a 
secondary anti-mouse CY3-conjugated antibody (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) diluted 1:300 in blocking buffer for 2 h at 
room temperature in the dark. After 3 washes in PBS, the cells were counterstained with 
4′, 6-diamino-2-phenylindole (1:500) (Invitrogen, Carlsbad, CA, USA) (100 ng/mL) for 
20 min at room temperature. The slides were washed three times in PBS and mounted.  
 
Tube formation assay 
An Angiogenesis Assay Kit (Kurabo, Osaka, Japan) was used according to the 
manufacturer’s instructions. Briefly, HUVECs, co-cultured with neonatal normal human 
dermal fibroblasts26, were treated with cilengitide (0.1 μM), RAMBO (5.0 × 102 pfu), 
and VEGF (10 ng/mL). Suramin (50 μM) was used as a positive anti-angiogenic control. 
The medium was changed every 3 days. After 10 days, the dishes were washed with 
PBS and fixed with 70% ethanol at 4°C. After the fixed cells were rinsed 3 times with 
PBS, the cells were incubated with mouse anti-human CD31 in PBS containing 1% 
BSA for 60 min. After washing 3 times with 1% BSA-PBS, the cells were incubated 
with a goat anti-mouse IgG AlkP conjugate. Metal-enhanced 3, 
3′-diamino-benzidine-tetrahydrochloride was used as the substrate, the reaction yielding 
a dark reddish-brown insoluble end-product. Finally, the cells were washed 5 times with 
PBS and viewed under a microscope (BZ-8000; Keyence, Osaka, Japan). Tube 
formation was counted under high magnification (×20), and the average tube area in 3 
hot spots was taken as the tube formation per view field. Tube formation was counted in 
at least 3 dishes. 
 
Endothelial cell migration assay (scratch wound assay) 
U251 glioma cells were infected with RAMBO or HSVQ (MOI: 2), and after 14 h, the 
CM was harvested, cellular debris was removed by centrifugation, and free floating 
viral particles were removed by further centrifugation at approximately 28,000 × g for 1 
h. For the endothelial cell migration assays, early passage HMVEC-d (passage 3) were 
purchased from Lonza (Basel, Switzerland). The cells were used between passages 4 
and 6, and they were maintained in endothelial growth media. HMVEC-d were plated 
onto a 24-well dish and allowed to grow to confluence. A thin line was made with a 
sterile 1000 μL pipette tip in the middle of the well and they were incubated with CM 
derived from U251 glioma cells (prepared in 2% FBS DMEM as described previously) 
and the indicated concentration of cilengitide was added. HMVEC-d were incubated for 
12 h at 37°C to allow cellular migration into the denuded area, and they were assessed 
by phase contrast microscopy.  
 
Virus yield assay 
To assess virus yield, U87ΔEGFR glioma cells were seeded on 6-well plates at 3.0 × 
105 cells per well. The cells were infected with RAMBO at an MOI of 0.1, and after 3 h 
of infection, we added either PBS or cilengitide (10 µM). At 36 h after infection, the 
glioma cells were harvested by scraping, and lysed by freezing and thawing three times. 
Cellular debris was removed by centrifugation, and the number of infectious viral 
particles (pfu) in the cells was assessed using a standard viral titration assay. 
 
Cytotoxicity assays 
The cytotoxicity of U251 Gli36, and U87ΔEGFR glioma cells was analyzed by the 
WST-1 quantitative colorimetric assay for cell survival according to the manufacturer’s 
instructions (Roche Molecular Biochemicals, Mannheim, Germany). This assay detects 
living, but not dead, cells, and the generated signal depends on the degree of cell 
activation. We seeded 1.0 × 104 cells/well in 96-well plates and they were left to attach 
at 37°C. Subsequently, the cells were treated with saline, cilengitide, RAMBO, or 
RAMBO and cilengitide combined. The cell lines were treated with the indicated 
concentration of cilengitide or the indicated MOI. Cell survival was measured at the 
indicated time points by adding the reaction solution (10 μL) to 100 μL of culture 
medium per well. The samples were then incubated for an additional 60–150 min at 
37°C in a humidified atmosphere of 5% CO2 and 95% air. The absorption of the 
samples was measured with a Thermo Scientific Multiskan® FC Microplate Photometer 
(Thermo Fisher Scientific, Inc., Mississauga, Ontario, Canada) at 450 nm wavelength 
using a 620 nm reference filter. The amount of formazan dye formed directly correlates 
to the number of metabolically active, viable cells. After subtraction of the background 
absorption, the mean value of the untreated control cells was set as 100%.  
 
Caspase assays 
Activity assay for caspase-8 and -9 
Caspase-8 and -9 levels were measured using a FLICE/Caspase-8 Colorimetric Assay 
Kit and Caspase-9 Colorimetric Assay Kit (BioVision, Mountain View, CA, USA), 
respectively, according to the manufacturer’s instructions. Briefly, U87ΔEGFR glioma 
cells were seeded in five 10-cm dishes (1.0 × 106 cells per dish), and after confirmation 
of their attachment, they were treated with culture medium containing cilengitide (10 
μM), RAMBO (MOI 0.1), and with a combination of RAMBO (same as above) and 
cilengitide in triplicate. At 16 h after adding the reagents and oncolytic virus, the cells 
were harvested and lysed using a cell lysis buffer. We centrifuged the cell lysate and 
harvested the supernatant, and the caspase solutions were then added. After incubation 
with these substrates for 1–2 h, the absorption of each group was measured by using a 
microplate reader.  
 
Activity assay for caspase-3/7 
Caspase-3/7 activity levels were measured using the CellEvent™ Caspase-3/7 Green 
Detection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
protocol. Briefly, U87ΔEGFR glioma cells were seeded in 96-well plates (10,000 cells 
per well), and after confirmation of their attachment, they were treated with culture 
medium containing cilengitide (10 μM), RAMBO (MOI 0.1), and with a combination of 
RAMBO (same as above) and cilengitide in triplicate. The caspase solution was added 
at 16 h after adding the reagents and oncolytic virus. Before and after incubation with 
these substrates, the fluorescence intensity of each well was measured using a 
microplate reader. We determined the caspase activity by measuring the fluorescence 
intensity and subtracted the background fluorescence of each well. 
 
Animal surgery and treatment 
All animal experiments were performed according to the guidelines of the 
Subcommittee on Research Animal Care of the Okayama University and were approved 
by the Institutional Review Board. Athymic nude mice (6–8-week-old balb/c-nu/nu; 
CLEA Japan, Inc., Tokyo, Japan) were used for all studies. For intracranial tumor 
studies, the mice were anesthetized with ketamine and somnopentyl and fixed in a 
stereotactic apparatus (Narishige, Tokyo, Japan) with their skull exposed. A burr hole 
was made at 1 mm posterior and 3 mm lateral from the bregma, and a Hamilton syringe 
(Hamilton, Reno, NV, USA) was then inserted to a depth of 3 mm below the brain 
surface. Then, 2 μL of 2.0 × 105 U87ΔEGFR glioma cells were slowly injected into the 
brain at a rate of 1 μL per min. The syringe was kept in place for 5 min after the 
injection and then slowly retracted to minimize backflow. We cleaned the skull, sealed 
the hole with bone wax, and sutured the incision. Seven days after the implantation of 
the U87ΔEGFR cells (105 cells), anesthetized mice were stereotaxically inoculated with 
5.0 × 104 pfu of RAMBO at the same location. Nine days after the implantation of the 
U87ΔEGFR cells, the mice were treated with either cilengitide (200 μg/100 μL PBS) or 
PBS intraperitoneally 3 times a week. The animals were observed daily and were 
sacrificed when they showed signs of morbidity. 
 
Statistical analysis 
The Mann-Whitney U test was used to analyze changes in cell death, HMVEC-d 
migration assay, and caspase assay data. Data are presented as the means ± standard 
error. P values < less than 0.05 were considered statistically significant in the 
Mann-Whitney U test. Kaplan-Meier curves were compared using the log-rank test. All 
statistical analysis was performed using SPSS statistical software (version 20; SPSS, 
Inc., Chicago, IL, USA). 
 
Results 
Antiangiogenic effect of combination treatment in the tube formation assay  
To investigate the antiangiogenic effect of RAMBO and cilengitide, the tube formation 
assay was performed using human umbilical vein endothelial cells (HUVECs) 
co-cultured with fibroblasts. When HUVECs were cultured in the presence of vascular 
endothelial growth factor (VEGF), efficient tube formation was observed. Conversely, 
an anti-VEGF drug (suramin: 50 μM) efficiently inhibited tube formation. Both 
RAMBO and cilengitide inhibited tube formation in HUVECs. Moreover, RAMBO 
and cilengitide combination treatment significantly inhibited tube formation compared 
to RAMBO or cilengitide monotherapy. Quantitative analysis of tube area confirmed 
that RAMBO and cilengitide efficiently inhibited in vitro angiogenesis, and 
combination treatment reduced angiogenesis more intensively than monotherapy 
(RAMBO and cilengitide combination: 8.4 × 103 ± 2.1 × 102 pixels; vs. RAMBO; 1.3 
× 103 ± 1.3 × 102 pixels, P = 0.009: vs cilengitide: 1.4 × 103 ± 3.5 × 102 pixels, P = 
0.028, respectively) (Figure 1). 
 
Inhibition of endothelial cell migration with combination treatment 
HMVEC-d were assayed for movement after 12 h of exposure to the conditioned 
medium (CM) of cells treated with HSVQ or RAMBO plus cilengitide. Wound closure 
was significantly reduced by treatment with RAMBO and cilengitide CM. The rate of 
wound closure was decreased by cilengitide in a dose-dependent manner. Especially, 
combining cilengitide with the CM of RAMBO-treated cells significantly decreased 
wound closure compared to combining cilengitide (1, 5, and 10 µM) with the CM of 
HSVQ-treated cells (P = 0.0102, P = 0.0019, and P = 0.0002, respectively). This assay 
indicated that treatment with RAMBO and cilengitide combined induced a synergistic 
suppressive effect on endothelial cell migration (Figure 2). 
 
Effect of cilengitide on oncolytic virus replication in vitro 
The difference in the replication capability of RAMBO was evaluated between glioma 
cells treated with RAMBO monotherapy and those treated with RAMBO and cilengitide 
combined. The viral yield at 36 h after infection of U87ΔEGFR glioma cells was 
determined at a multiplicity of infection (MOI) of 0.1. Virus (RAMBO)-infected glioma 
cells treated with cilengitide had significantly higher titers of infectious virus compared 
with those treated with phosphate-buffered saline (PBS) (viral titer for RAMBO and 
cilengitide combined versus RAMBO monotherapy = 2.8 × 105 ± 1.6 × 105 plaque 
forming units (pfu) versus 6.5 × 104 ± 2.1 × 104 pfu, respectively, and the mean fold 
increase in GFP expression for RAMBO and cilengitide combined versus RAMBO 
monotherapy = 4.3, P = 0.0273) (Figure 3).  
 
Immunocytochemical analysis of αvβ3 and αvβ5 integrin expression in glioma cell 
lines 
Immunofluorescence assays were conducted to determine the expression of αvβ3 and 
αvβ5 integrins in U251, Gli36, and U87ΔEGFR glioma cell lines. Most of these 
cultured cell lines were immunopositive for αvβ3 and αvβ5. The percentage of cells 
staining for αvβ3 and αvβ5 was as follows: U251: αvβ3 95.3 ± 1.3%, αvβ5 93.4 ± 6.7%; 
Gli36: αvβ3 98.3 ± 2.9%, αvβ5 97.0 ± 5.2%; U87dEGFR: αvβ3 95.1 ± 4.3% αvβ5 87.1 
± 6.0% (Supplementary figure 1).  
 
Cytotoxic effect of combination treatment 
The cytotoxic effect of RAMBO and cilengitide on glioma cells was investigated in 
vitro. Figure 4 shows the results of the water-soluble tetrazolium (WST)-1 assay, 
which demonstrate the cytotoxicity effect of RAMBO and cilengitide. Glioma cell lines 
were incubated with the indicated concentration of cilengitide or the indicated MOI. 
After 36 h, cell viability was assessed by the WST-1 proliferation/viability assay. Cell 
survival after a 36 h incubation was decreased more by treatment with a high MOI than 
with cilengitide. Moreover, the addition of cilengitide enhanced the reduction of cell 
viability. This result indicated that the combination of RAMBO with cilengitide induced 
additive or synergistic cytotoxicity.  
 
Apoptotic effect of RAMBO and cilengitide combination treatment 
U87ΔEGFR glioma cells were treated with cilengitide (10 µM), with RAMBO (MOI 
0.1), and with RAMBO and cilengitide combined (same as above). At 16 h after 
infection with RAMBO and 13 h after adding cilengitide or PBS, glioma cells were 
harvested and the activity of caspase-8,-9, and -3/7 was evaluated. In the caspase-8  
assay, the relative absorption (RA) of U87ΔEGFR cell clusters treated with cilengitide 
was significantly higher than of those treated with control (caspase-8: 0.33 ± 0.065 RA 
vs. 0.27 ± 0.054 RA, P = 0.043) (Figure 5A). In the caspase -9 assay, the (RA) of 
U87ΔEGFR cell clusters treated with RAMBO was significantly higher than of those 
treated with control (0.33 ± 0.027 vs. 0.029 ± 0.029, P = 0.043) (Figure 5B).  
The activity of caspase-3/7 was also increased in treated cells; especially, a significant 
increase of caspase-3/7 activity was observed in cells treated with cilengitide and with 
RAMBO and cilengitide combined. Moreover, there was a significant increase in 
caspase-3/7 activity in cells treated with combination therapy compared to RAMBO 
monotherapy, cilengitide monotherapy, and untreated cells (P = 0.0008, P = 0.0117, and 
P = 0.0008, respectively) (Figure 6). 
 
Effect of cilengitide treatment on the therapeutic efficacy of RAMBO in a 
xenograft mouse model 
 
The antitumor effect of RAMBO, cilengitide, and RAMBO and cilengitide combined 
was tested in mice bearing intracerebral glioma (U87ΔEGFR). Kaplan-Meier survival 
curves were used to assess the survival time of the U87ΔEGFR mouse glioma model 
treated with PBS, cilengitide, RAMBO, and RAMBO and cilengitide combined. There 
was a significant increase in the survival of mice treated with combination therapy 
compared to RAMBO monotherapy, cilengitide monotherapy, or untreated mice 
(median survival = 38.5, 29, 19, and 19 days, respectively) (P < 0.005, P < 0.001, and P 
< 0.001, respectively) (Figure 7). 
 
Discussion 
Our results indicate that the combination of RAMBO and cilengitide significantly 
inhibited tube formation compared to RAMBO or cilengitide monotherapy. Moreover, 
RAMBO and cilengitide combination treatment induced a synergistic suppressive effect 
on endothelial cell migration. The addition of cilengitide enhanced the reduction of cell 
viability and a significant increase of caspase-8, -9, and -3/7 activity was observed in 
cells treated with cilengitide and with RAMBO and cilengitide combined. Furthermore, 
the survival time of mice bearing intracerebral glioma treated with combination therapy 
was significantly increased compared to monotherapy. 
 
1) The advantage of the RAMBO virus on OV therapy 
We have shown that the reduction of tumoral blood vessel density by a single dose of 
cilengitide treatment prior to oncolytic HSV-1 treatment reduced oncolytic 
virus-induced hyperpermeability and tumor inflammation, and prolonged tumoral viral 
propagation, thereby enhancing the antitumor efficacy of the oncolytic virus 21. In 
addition, we showed that RAMBO had a significantly greater antitumor effect 
compared to OV treatment alone 5. We suggested that the increased antitumor efficacy 
of RAMBO might be attributed to its ability to counter oncolytic virus-induced 
angiogenic changes in the tumor microenvironment. Certainly, in our experiments, we 
could have the antiangiogenic effect and apoptotic effect following treatment with 
RAMBO as single treatment.  
 
2) The advantage of combination therapy with cilengitide 
Several preclinical studies have shown an enhanced antitumor effect of cilengitide when 
administered in combinatorial therapeutic regimens 17-20. Mikkelsen et al. demonstrated 
that cilengitide dramatically amplified the efficacy of radiation therapy in an animal 
glioma model 27. We demonstrated the enhanced therapeutic efficacy of an oncolytic 
virus on experimental glioma following pretreatment with cilengitide 21. OV treatment 
of experimental rat gliomas results in vascular hyperpermeability of the tumor. In this 
study, we reported the effects of a novel oncolytic HSV virus and the systemic injection 
of cilengitide. In addition, we also revealed that there was synergistic effect between 
cilengitide and viral injection. Especially, the combination of RAMBO with cilengitide 
induced a synergistic suppressive effect on endothelial cell migration compared to 
combining cilengitide with the CM of HSVQ-treated cells. Future studies will elucidate 
the relationship between Vstat120 expression and cilengitide.  
 
3) A role for apoptosis in combination treatment with oncolytic virus and 
cilengitide 
Previously, the cytotoxic effect of cilengitide was clearly shown. Recently, similar 
changes in HUVECs have been reported for S 36578-2, a novel RGD mimetic that 
selectively activates the αvβ3 and αvβ5 integrins 28. This compound induces cell 
detachment and apoptosis by the direct activation of caspase-8 29. In our study, 
cilengitide inhibited integrin binding and activated caspase-8. This caspase-8 activation 
effect of cilengitide would enhance the effect of other cytotoxic therapies. On the other 
hand, a previous study showed the induction of increased mitochondrial membrane 
permeability, a surrogate marker for apoptosis, in an oncolytic virus derived from 
HSV-1 30. Prominent and early caspase-9 processing is compatible with the 
mitochondrial triggering of the caspase cascade, as reported previously [37]. In our data, 
especially, a significant increase of caspase -3/7 activity was observed in cells treated 
with both RAMBO and cilengitide. This combination between the 
mitochondria-dependent pathway with caspase-9 activation and the death-receptor 
pathway, including caspase-8 activation, might be more efficient for inducing apoptosis 
than a single pathway (Figure 8). 
 
4) Future directions 
Cilengitide monotherapy or combination treatment with radiation and/or temozolomide 
is well tolerated and exhibits modest antitumor activity 20, 31, 32. The CENTRIC 
controlled phase III study was launched in 2008, with primary outcome measures due in 
September 2012. The results of this and other clinical studies are expected with great 
hope and interest for combination therapy with an oncolytic virus. In addition, 
cysteine-rich 61 (CYR61) is known to interact with integrins, such as αvβ3, α6β1, αvβ5, 
and αIIβ3, which leads to a wide range of biological activity, including cell adhesion, 
migration, and invasion 33. Previously, we showed that the induction of CYR61 after 
oncolysis results in the production of a proangiogenic glioma ECM that plays a key role 
in the neovascularization of a residual tumor. Moreover, exogenous CYR61 in glioma 
ECM is reported to orchestrate a cellular antiviral response that reduces viral replication 
and limits the efficacy of the oncolytic virus34. Future studies will investigate the 
mechanism of the CYR61-induced antitumor effect of RAMBO and cilengitide 
combination therapy. Recently, Yoo et al. described the construction and testing of a 
novel HSV-1-derived oncolytic virus, 34.5ENVE (viral ICP34.5 Expressed by Nestin 
promoter and Vstat120 Expressing), for the treatment of cancer35. We also intend to use 
this new virus in combination with cilengitide. 
In conclusion, our results indicated that cilengitide enhaced vasculostatin-expressing 
OV therapy for malignant glioma and unveiled a rationale for designing future clinical 
trials combining these two agents. 
 
Acknowledgements 
We thank H. Wakimoto, M. Arao, and A. Ishikawa for their technical assistance. 
This study was supported by grants-in-aid for Scientific Research from the Japanese 
Ministry of Education, Culture, Sports, Science, and Technology to K.K. (No. 
20890133; No. 21791364), and T.I. (No. 19591675; No. 22591611). 
 
Conflict of interest 
We declare that we have no conflict of interest. 
 
References 
1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 
2005; 109(1): 93-108. 
 
2. Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B. Advances in oncolytic 
virus therapy for glioma. Recent Pat CNS Drug Discov 2009; 4(1): 1-13. 
 
3. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A et al. Oncolytic 
HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 
2008; 16(8): 1382-91. 
 
4. Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA et al. Vasculostatin 
inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis 
through a CD36-dependent mechanism. Cancer Res 2009; 69(3): 1212-20. 
 
5. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P et al. 
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. 
Mol Ther 2010; 18(2): 285-94. 
 
6. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110(6): 
673-87. 
 
7. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8(5): 
724-30. 
 
8. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin 
alphavbeta3. Important Adv Oncol 1996: 69-87. 
 
9. Varner JA, Emerson DA, Juliano RL. Integrin alpha 5 beta 1 expression negatively 
regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 1995; 6(6): 
725-40. 
 
10. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. 
Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 
270(5241): 1500-2. 
 
11. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 
for angiogenesis. Science 1994; 264(5158): 569-71. 
 
12. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al. Integrin 
alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of 
angiogenic blood vessels. Cell 1994; 79(7): 1157-64. 
 
13. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: 
multitalented molecules in a balancing act. Cell Tissue Res 2003; 314(1): 131-44. 
 
14. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA. Requirement of the integrin 
beta 3 subunit for carcinoma cell spreading or migration on vitronectin and 
fibrinogen. J Cell Biol 1992; 117(5): 1101-7. 
 
15. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA et al. 
Preferential susceptibility of brain tumors to the antiangiogenic effects of an 
alpha(v) integrin antagonist. Neurosurgery 2001; 48(1): 151-7. 
 
16. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL et al. Crystal 
structure of the extracellular segment of integrin alpha Vbeta3. Science 2001; 
294(5541): 339-45. 
 
17. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. 
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with 
radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. 
Cancer Res 2002; 62(15): 4263-72. 
 
18. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R et al. Inhibition of 
alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor 
effects of radiotherapy. Clin Cancer Res 2005; 11(17): 6270-9. 
 
19. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P et al. The integrin 
antagonist cilengitide increases the antitumor activity of temozolomide against 
malignant melanoma. Oncol Rep 2008; 19(4): 1039-43. 
 
20. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S et al. 
Randomized phase II study of cilengitide, an integrin-targeting 
arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin 
Oncol 2008; 26(34): 5610-7. 
 
21. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G et al. Effect 
of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J 
Natl Cancer Inst 2007; 99(23): 1768-81. 
 
22. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y et al. Depletion of 
peripheral macrophages and brain microglia increases brain tumor titers of 
oncolytic viruses. Cancer Res 2007; 67(19): 9398-406. 
 
23. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. 
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune 
responses. Proc Natl Acad Sci U S A 2006; 103(34): 12873-8. 
 
24. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing 
ICP34.5 under control of a nestin promoter increases survival of animals even when 
symptomatic from a brain tumor. Cancer Res 2005; 65(7): 2832-9. 
 
25. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid 
method to generate multiple oncolytic HSV vectors and their in vivo evaluation 
using syngeneic mouse tumor models. Gene Ther 2006; 13(8): 705-14. 
 
26. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN. An in vitro model 
of angiogenesis: basic features. Angiogenesis 1999; 3(4): 335-44. 
 
27. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K et al. Radiation 
sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. 
Int J Cancer 2009; 124(11): 2719-27. 
 
28. Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, Hickman JA et 
al. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces 
anoikis and not integrin-mediated death in human endothelial cells. Blood 2006; 
108(9): 3035-44. 
 
29. Onishi M, Kurozumi K,Ichikawa T, Kurozumi K, Kentaro Fujii, Satoshi Inoue,  
E.Antonio Chiocca, Balveen Kaur, Isao Date Omics analysis cilengitide treatment of 
malignant glioma. Congress of Neurosurgery 2012: submitted. 
 
30. Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA et al. Cytotoxicity, 
apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide 
reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing 
radiation. Cancer Gene Ther 2000; 7(7): 1051-9. 
 
31. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting 
arginine-glycine-aspartic acid peptide with promising activity for glioblastoma 
multiforme. Expert Opin Investig Drugs 2008; 17(8): 1225-35. 
 
32. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G et al. A safety run-in 
and randomized phase 2 study of cilengitide combined with chemoradiation for 
newly diagnosed glioblastoma (NABTT 0306). Cancer 2012. 
 
33. Walsh CT, Radeff-Huang J, Matteo R, Hsiao A, Subramaniam S, Stupack D et al. 
Thrombin receptor and RhoA mediate cell proliferation through integrins and 
cysteine-rich protein 61. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 2008; 22(11): 4011-21. 
 
34. Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J et al. Extracellular matrix protein 
CCN1 limits oncolytic efficacy in glioma. Cancer Res 2012; 72(6): 1353-62. 
 
35. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K et al. Antitumor 
efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing 
oncolytic virus. Mol Ther 2012; 20(2): 287-97. 
 
 
 
 
 
Figure legends 
Figure 1: Inhibition of endothelial cell tube formation. HUVECs were treated with 
medium containing VEGF-A, RAMBO, and cilengitide, and then assayed by the 
KURABO Angiogenesis Kit. A: The representative images show tube formation of 
HUVECs. a: VEGF-A (10 ng/mL), b: VEGF-A + RAMBO (5×102 pfu), c: VEGF-A + 
cilengitide (0.1 μM), and d: VEGF-A+RAMBO (5.0 ×102 pfu) + cilengitide (0.1 μM).  
B: Significant reduction in tube formation of HUVECs treated with RAMBO and 
cilengitide combined compared to RAMBO or cilengitide monotherapy (*: P = 0.0090 
and **: P = 0.028, respectively). 
 
Figure 2: Inhibition of endothelial cell migration. HMVEC-d were incubated with CM 
derived from U251 glioma cells treated with HSVQ or RAMBO. Additionally, they 
were treated with the indicated concentration of cilengitide. A: Representative images 
from the scratch wound assay. HMVEC-d were assayed for movement after 12 h of 
exposure to CM with HSVQ or RAMBO plus cilengitide. B: Higher concentrations of 
cilengitide decreased the rate of wound closure. Especially, wound closure was 
significantly decreased in cells treated with CM from RAMBO-treated cells compared 
with CM from HSVQ-treated cells (*: P = 0.010, **: P = 0.0019, and ***: P = 0.00020, 
respectively).  
 
Figure 3: Enhancement of viral replication in glioma cells. U87ΔEGFR glioma cells 
were plated on a 6-well plate and infected with RAMBO, and then either PBS or 
cilengitide was added to them. At 36 h after infection, the number of infectious viral 
particles in the cells was assessed using a standard viral titration assay. There was a 
significant increase in the titer of cells treated with RAMBO and cilengitide combined 
compared to those treated with PBS (mean fold increase in the expression of GFP for 
the RAMBO and cilengitide combination treatment versus RAMBO monotherapy = 4.3, 
P = 0.0273). 
 
Figure 4: Cytotoxicity effect of RAMBO, cilengitide, and RAMBO and cilengitide 
combined on glioma cell lines. Glioma cells grown in 96-well plates were treated for 36 
h with various MOIs of RAMBO and for 33 h with various concentrations of cilengitide. 
Cell viability was determined using the WST-1 assay. For the most part, the higher was 
the MOI, the greater the reduction in cell survival. Moreover, the addition of cilengitide 
enhanced the reduction of cell viability. U251 glioma cells (A): Gli36 glioma cells (B): 
U87ΔEGFR glioma cells(C).  
 
Figure 5: Induction of Caspase-8 and -9 by treatment with RAMBO, cilengitide, and 
RAMBO and cilengitide combined in vitro. A: Caspase-8 activity assay. U87ΔEGFR 
glioma cells were treated with cilengitide (10 µM), with RAMBO (MOI 0.1), and with 
RAMBO and cilengitide combined (same as above). At 16 h after infection with 
RAMBO and 13 h after adding cilengitide or PBS, caspase activity was evaluated in the 
cells using a FLICE/Caspase-8 Colorimetric Assay Kit. There was a significant increase 
in caspase-8 activity in glioma cells treated with cilengitide compared to those of 
control. The symbol (*) show a significant increase in caspase-8 activity. B: Assay of 
caspase-9 activity. U87ΔEGFR glioma cells were treated as mentioned, and evaluated 
using a Caspase-9 Colorimetric Assay Kit. There was a significant increase in caspase-9 
activity in glioma cells treated with RAMBO compared to those of (A: *: P = 0.043, B: 
*: P = 0.043, respectively).  
 
Figure 6: Induction of caspase-3/7 following treatment with RAMBO, cilengitide, and 
RAMBO and cilengitide combined in vitro. Assay of caspase-3/7 activity. U87ΔEGFR 
glioma cells were treated with cilengitide, RAMBO, and RAMBO and cilengitide 
combined (same as above). At 16 h after infection with RAMBO and 13 h after adding 
cilengitide or PBS, caspase activity was evaluated in the cells using the CellEvent™ 
Caspase-3/7 Green Detection Reagent. Caspase-3/7 activity was increased in the treated 
cells; especially, a significant increase of caspase-3/7 activity was observed in the cells 
treated with cilengitide and RAMBO and cilengitide combined. There was a significant 
increase in the activity of caspase-3/7 in the cells treated with the combination therapy 
compared to RAMBO monotherapy, cilengitide monotherapy, and untreated cells (P = 
0.0008, P = 0.0117, and P = 0.0008, respectively).  
 
Figure 7: Kaplan–Meier survival curves of mice implanted with intracranial 
U87ΔEGFR glioma cells treated with PBS, cilengitide, RAMBO, or RAMBO and 
cilengitide combined. Athymic nude mice bearing intracranial U87ΔEGFR gliomas 
were treated with 0.5 × 105 pfu RAMBO at 7 days after tumor cell implantation. At 9 
days after tumor cell implantation, cilengitide was administered 3 times per week 
intraperitoneally at 200 μg/100 μL PBS. The mice were then closely monitored for 
survival. There was a significant increase in the survival of mice treated with 
combination therapy compared to RAMBO or cilengitide monotherapy (median 
survival = 38.5, 29, and 19 days, respectively) (P < 0.005 and P < 0.001, respectively). 
 
Figure 8: Apoptotic pathways whereby RAMBO and cilengitide combination exerts 
this cytotoxic effect: the mitochondrial pathway and the death receptor pathway 
 
Supplementary figure 1: Expression of αvβ3 and αvβ5 integrins on the surface of 
HMVEC-d. The expression of αvβ3 and αvβ5 was recognized on the U251 (A), Gli36 
(B), and U87ΔEGFR (C) cells. 
 








